Shire PLC (SHPG) Shares Bought by UBS Asset Management Americas Inc.
UBS Asset Management Americas Inc. increased its position in Shire PLC (NASDAQ:SHPG) by 10.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 541,749 shares of the biopharmaceutical company’s stock after buying an additional 53,077 shares during the period. UBS Asset Management Americas Inc. owned 0.18% of Shire PLC worth $105,023,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Franklin Street Advisors Inc. NC raised its stake in Shire PLC by 3.6% in the second quarter. Franklin Street Advisors Inc. NC now owns 5,697 shares of the biopharmaceutical company’s stock worth $1,049,000 after buying an additional 197 shares during the last quarter. FirstMerit Bank N A Trustee acquired a new stake in Shire PLC during the second quarter worth $212,000. Capital Asset Advisory Services LLC acquired a new stake in Shire PLC during the second quarter worth $735,000. TT International acquired a new stake in Shire PLC during the second quarter worth $1,184,000. Finally, Chevy Chase Trust Holdings Inc. acquired a new stake in Shire PLC during the second quarter worth $894,000. 22.78% of the stock is owned by institutional investors and hedge funds.
Shares of Shire PLC (NASDAQ:SHPG) traded up 0.06% on Monday, hitting $175.33. 530,482 shares of the company were exchanged. The company has a 50-day moving average price of $180.43 and a 200 day moving average price of $187.45. The firm has a market cap of $52.22 billion, a P/E ratio of 36.44 and a beta of 1.46. Shire PLC has a 52-week low of $147.60 and a 52-week high of $215.05.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Tuesday, November 1st. The biopharmaceutical company reported $3.17 EPS for the quarter, missing the Zacks’ consensus estimate of $3.21 by $0.04. The business earned $3.45 billion during the quarter, compared to analyst estimates of $3.57 billion. Shire PLC had a net margin of 1.62% and a return on equity of 14.81%. Shire PLC’s revenue was up 108.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.24 earnings per share. Analysts predict that Shire PLC will post $12.93 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/28/shire-plc-shpg-shares-bought-by-ubs-asset-management-americas-inc.html.
Several research firms recently commented on SHPG. Piper Jaffray Cos. set a $201.00 price target on shares of Shire PLC and gave the company a “hold” rating in a research report on Saturday, October 1st. Leerink Swann restated a “buy” rating on shares of Shire PLC in a research report on Saturday, October 1st. RBC Capital Markets restated an “outperform” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Jefferies Group restated a “buy” rating on shares of Shire PLC in a research report on Wednesday, August 17th. Finally, TheStreet lowered shares of Shire PLC to a “hold” rating in a research report on Thursday, August 4th. Four analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $222.06.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.